drug
ketamine
Phase 3updated 6mo agoby $NRXP NRX Pharmaceuticals, Inc.
Phase 3community read0 votes
🐶 often sniffed alongside
top 8- drugKETAMINE HYDROCHLORIDE59 co-mentions · 32 sources
- drugKetalar59 co-mentions · 32 sources
- tagApproval58 co-mentions · 29 sources
- tagRecall10 co-mentions · 10 sources
- tagPain4 co-mentions · 1 sources
- drugflumazenil4 co-mentions · 4 sources
- tagOncology2 co-mentions · 1 sources
- tagBreast Cancer2 co-mentions · 1 sources
all catalysts(1)
Trials studying ketamine
- phase3A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression
- phase3A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
- phase4A Study of Esketamine Nasal Spray in Korean Participants With Treatment-resistant Depression
- —Anesthetics and Analgesics in Children
- phase3Multi-center RCT of IV Ketamine Efficacy and Safety in Chronic Daily Headaches
- phase1Ketamine Biomarker Validation
- phase4A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment
- phase1Study of SAGE-904 Using a Ketamine Challenge to Evaluate Electrophysiology, Safety, Tolerability, and Pharmacokinetics in Healthy Participants
News(10)
- HHS pumps up to $25M into ibogaine, other psychotropic drugs on Veteran’s DayIbogaine, which operates via a “matrix pharmacology,” has long been a focus of Health Secretary Robert F. Kennedy Jr. and the Trump administration.biospace · 3d ago
- ARPA-H bets $4.9 million on ibogaine for PTSD treatment in veteransThe U.S. department of health and human services announced a $4.9 million bet to advance the development of ibogaine for post-traumatic stress disorder (PTSD).fiercebiotech · 4d ago
- Delix raises $100M to advance at-home psychedelic without hallucinatory effectsThe series C raise, co-led by Johnson & Johnson’s venture capital arm, will help Delix Therapeutics push its novel psychedelic asset into mid-stage development for major depressive disorder.biospace · 6d ago
- Delix raises $100M to advance at-home psychedelic without hallucinogenic effectsThe series C raise, co-led by Johnson & Johnson’s venture capital arm, will help Delix Therapeutics push its novel psychedelic asset into mid-stage development for major depressive disorder.biospace · 6d ago
- J&J-backed Delix drums up $100M series C for non-hallucinatory psychedelic for depressionDelix Therapeutics has raised $100 million in a series C round backed by the likes of Johnson & Johnson to advance a phase 2-ready non-hallucinatory psychedelic therapy for depression.fiercebiotech · 8d ago
- STAT+: Most cancer drugs approved by European regulators lack a high clinical benefit, analysis findsMost new cancer medicines approved by European regulators over a recent four-year period do not offer high clinical benefit, a new analysis finds.stat · 24d ago
- STAT+: Up and down the ladder: The latest comings and goingsFrom new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.stat · 24d ago
- STAT+: Pharmalittle: We’re reading about a cancer vaccine, an experimental pancreatic cancer drug, and moreA personalized mRNA cancer vaccine reduced the risk of disease recurrence in patients with melanoma by 42% compared to a standard treatmentstat · 24d ago
- STAT+: Gilead to pay $45 million to settle kickback charges filed by Texas attorney generalGilead Sciences agreed to pay $45 million to settle allegations of paying kickbacks that improperly influenced prescriptions paid for by the Texas Medicaid programstat · 25d ago
- STAT+: Pharmalittle: We’re reading about a U.S. rule on Chinese deals, Belgium refusing Mounjaro coverage, and moreU.S. is poised to issue a proposed rule that would subject outbound licensing deals with Chinese biotech companies to additional scrutinystat · 25d ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that